Effects of topical pimecrolimus 1% on high-dose ultraviolet B-irradiated epidermal Langerhans cells.
Some studies reported no changes in the number of epidermal Langerhans cells (LC) that were observed in mice treated with pimecrolimus, and low-dose stimulated solar radiation (once)-induced changers in LC are minimally affected by pimecrolimus. This study is to investigate the effects of topical pimecrolimus 1% on high-dose ultraviolet B (UVB)-irradiated epidermal LC. Forty human foreskin tissues were randomly divided into 4 groups of 10 tissues each: Group A, control; Group B, pimecrolimus 1% (once)-only; Group C, 180 mJ/cm(2) UVB (once)-only; Group D, UVB+pimecrolimus. Each tissue was cut into 4 pieces corresponding to 4 time points. All the tissues were cultured at 37 °C. After being treated, the tissues were collected respectively and processed for immunohistochemical staining and immunofluorescence staining. For UVB-only group, epidermal CD1a(+) LC number at 18h decreased from 39.6 ± 8.30 to 22.3 ± 2.26/5 high magnification, compared to CD1a(+) LC number at 0 h (P<0.01). The CD1a(+) LC number of UVB-only group was significantly less than other groups at 18 h, 24h and 48 h (P<0.05, respectively). Similar results were obtained with immunofluorescence staining for CD 1a and immunohistochemical staining for Langerin. The numbers of epidermal HLA-DR(+) LC had no significant differences among all groups at different time points. Our study found a single 180 mJ/cm(2) UVB irradiation significantly reduced epidermal LC numbers at 18 h, 24h and 48 h, however, topical pimecrolimus could reverse these changes. UVB plus pimecrolimus treatment did not affect human LC maturation.
Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
ZhiQiang
Z
Yin
JiaLi
J
Xu
ZhiHong
Z
Zhang
Dan
D
Luo
D000287:Administration, Topical; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004307:Dose-Response Relationship, Radiation; D052816:Foreskin / Q000166:cytology / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D007801:Langerhans Cells / Q000187:drug effects* / Q000528:radiation effects*; D008297:Male; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D046509:Tissue Culture Techniques; D014466:Ultraviolet Rays / Q000009:adverse effects*
D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus